KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug
KemPharm, Inc. (KMPH)
Last kempharm, inc. earnings: 2/28 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.kempharm.com/investor-overview
Company Research
Source: GlobeNewswire
Highlights of KP415.A01 Oral HAP Trial Results: Oral Human Abuse Potential Trial with KP415 Prodrug (KP415.A01) Clinical Findings Mean Drug Liking (Emax) of KP415 Prodrug (serdexmethylphenidate) at both 120 mg and 240 mg doses were statistically significantly lower than Focalin® XR at 80 mg Mean Drug Liking (Emax) of KP415 Prodrug at 120 mg dose was statistically significantly lower than 60 mg of phentermine, a schedule IV controlled substance CORALVILLE, Iowa, Sept. 11, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced topline results from its oral human abuse potential (HAP) clinical trial of serdexmethylphenidate (SDX, a prodrug of d-methylphenidate, or KP415 Prodrug),
Show less
Read more
Impact Snapshot
Event Time:
KMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KMPH alerts
High impacting KemPharm, Inc. news events
Weekly update
A roundup of the hottest topics